Our client Julz, a healthcare investment company, was one of the investors in SurgaColl in their Series A. SurgaColl is a regenerative medicine company focussed on tissue repair. The funding allowed the company to establish a new commercial headquarters in Alderley Park, Cheshire which is one of the largest bioscience campuses in the UK with more than one million square feet of prime lab space. Julz, also closed a Series A round for Stent Tek in Q3 2017. Stent Tek makes a novel catheter system for minimally invasive vascular access.
Health Enterprise East (HEE) recently launched Medovate Ltd, a MedTech innovation development that’s designed to boost the financial and technical support available to NHS MedTech innovators. Medovate is backed by a £9 million of investment capital from NVM Private Equity and a private US investor. HEE says that Medovate is the first company dedicated to the development and commercialisation of innovative medical technologies from within the NHS, which will commercially benefit the NHS.
Our clients, Professor James Leiper, a scientist at the University of Glasgow and Dr. Simon Lambden, Cambridge University, the co-founders of Critical Pressure, recently completed a $10 million Series A round from Medicxi to develop a new drug to help patients in intensive care with severe sepsis. Critical Pressure is a virtual biopharmaceutical company developing products to treat vascular dysfunction and shock. The company says more than 37,000 people die from sepsis in the UK alone each year adding a significant demand on healthcare resources which are estimated to cost the NHS more than £1 billion a year.
Dr. Caroline Barelle, CEO Elasmogen Ltd and Orbital Diagnostics recently garnered nominations on their nominations in the 2018 Scottish Life Sciences Awards. Dr. Barelle was nominated as a finalist in the Rising Star category and Orbital in the innovation category.